Despite an expanded indication from the FDA and lower prices, patient access to these cholesterol-lowering medications remains a significant issue.

However, that one finding does not tell the whole story. Researchers also found that DOACs may increase a TAVR patient's risk of a disabling stroke.

Michael Garshick, MD, examines the role of inflammation in coronary disease development, detailing how this risk factor can be detected and treated.

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

Choosing between DOACs and VKAs could make a significant impact on patient outcomes, according to new findings published in the Journal of the American College of Cardiology.

However, the popular anti-inflammatory drug was linked to at least one other clinical benefit cardiologists should know about. 

The popular drugs, originally developed to treat diabetes, are being used more and more in the United States to help obese and overweight patients lose weight.  

Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease.